At ASCO 2019, Chicago, US, the Multiple Myeloma Hub were delighted to interview Jonathan L. Kaufman, Winship Cancer Institute of Emory University, Atlanta, US, about the safety and efficacy of the D-Rd regimen; daratumumab + lenalidomide + dexamethasone. The POLLUX study, recruited patients with relapsed/refractory multiple myeloma. This is an updated analysis, focusing on cytogenetics. The results found that high-risk patients significantly benefited from the addition of daratumumab to lenalidomide + dexamethasone. This was also seen in the standard-risk group indicating all cytogenetics subgroups benefited.
The European School of Haematology (ESH) is a not for profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH Conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in Haematology